The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity
Dosing The dose of semaglutide will be different for different patients
GLP-1s Reduce Heart Attacks and Mortality in PsA Patients This is the study that matters most for long-term outcomes
Inadequate sleep can contribute to increased hunger and appetite, disrupting metabolic and endocrine function to make you feel hungrier and, in turn, consume more
Early gastroparesis symptoms: acid reflux, heartburn, nausea and vomiting, abdominal distension or bloating, early satiety (getting full after only a few bites) Early kidney dysfunction-proteinuria, swelling of extremities (hands and feet), increased fatigue, and weakness
Because semaglutide reduces appetite, there's a theoretical worry that mothers might not eat enough calories to maintain good milk production